Severe Pediatric Myocarditis Linked to Parvovirus B19 Post-COVID-19 Surge

Overview

A multicenter observational study in England identified a marked increase in severe parvovirus B19–associated myocarditis cases in children during 2024, coinciding with heightened viral circulation post-COVID-19. Most affected children required intensive care, with high rates of inotrope use and some needing extracorporeal membrane oxygenation.

Background

Parvovirus B19 is a known cause of myocarditis and dilated cardiomyopathy in children. Following alerts of increased parvovirus B19 circulation in Europe and the UK in 2024, this study evaluated myocarditis cases linked to the virus across three major pediatric centers in England. The study compared cases before, during, and after the COVID-19 pandemic to assess changes in incidence and severity. Understanding the clinical presentation and outcomes of parvovirus B19–associated myocarditis is critical for timely diagnosis and management.

Data Highlights

Key Findings

• There was a notable increase in parvovirus B19–associated myocarditis cases in children during 2024 compared to previous years.
• Most children (93%) required intensive care admission, with a median ICU stay of 12 days.
• Severe cardiac dysfunction was common, with a median ejection fraction of 25% at presentation.
• High rates of inotrope use (88%) and invasive ventilation (70%) were observed; 15% required extracorporeal membrane oxygenation.
• Only 25% of cases had detectable parvovirus B19 IgM antibodies despite positive PCR, indicating recent infection with variable serologic response.
• Clinical presentations in 2024 were similar in severity and age distribution to cases before and during the COVID-19 pandemic.

Clinical Implications

Clinicians should consider parvovirus B19 infection in children presenting with severe myocarditis, especially given the increased viral circulation post-COVID-19. Diagnostic evaluation should include blood PCR and serology as part of a syndromic screen. Early recognition and intensive supportive care, including inotropes and mechanical support, are critical to improving outcomes.

Conclusion

This study highlights a significant post-pandemic surge in severe parvovirus B19–associated myocarditis in pediatric patients, underscoring the need for heightened clinical awareness and comprehensive diagnostic testing to guide management.

References

1. European Centre for Disease Prevention and Control/UK Health Security Agency 2024 -- Alerts on increased parvovirus B19 circulation
2. Great Ormond Street Hospital Clinical Audit 2024 -- Parvovirus B19–associated myocarditis study